RE: Every newspaper27 Nov 2020 14:45
I have emailed Sky and BBC
Dear Sir/Madam
Dear Sky News Team
I am writing to you in order to rise some awareness and express my disappointment in regards with the recent general media coverage about Covid-19 treatments.
Currently and mostly since the beginning of the pandemic, the majority of the UK Media channels have primarily focused only on vaccines and have, apart from some brief reports earlier this year seemingly forgotten about the treatments and therapeutic side of the matter in terms of new developments and progression made since the end of the summer.
In particular, I would like to bring to your attention Synairgen Ltd, which you have covered in your reports in April.
Based in Southampton and founded from an extremely experienced team, including the recently Knighted Prof Stephen Holgate, this company have made substantial progress in the fight against Covid-19 with their inhaled interferon beta drug SNG001.
They have now started a global phase 3 trial in 26 countries including UK, USA, Central and South America, whole Europe, South Africa and more.
Their previous phase 2 trial results, which have been already published in the Lancet Journal, have shown a 79% lower risk for patients of developing severe disease compared to the placebo arm being twice as likely to recover from Covid-19 as those on placebo.
This is a great English story from a UK Biotech and Research company which have been forgotten from the media.
This is in my opinion disappointing given the fact that the only reports the public can hear of are about vaccines vaccines and vaccines.
I appreciate the importance for the coverage in regards to vaccines and the need for immunisation in order to get through this unprecedented time, nevertheless therapeutics are also part of the puzzle both in the short and the long term.
They are equally relevant and must be taken into account from both media and government.
SNG001 is a broad spectrum antiviral which have been studied for almost fifteen years and have shown high efficacy in COPD, Asthma, Influenza like viruses and other viral pulmonary conditions.
Hence, if data from this fast tracked phase 3 trail would show the same efficacy as previously such drug could very well be a breakthrough drug as it has already demonstrated, for fighting the pandemic, save lives, protect the elderly and play a major role for the above mentioned medical conditions.
In conclusion, I would be pleased to see more extensive media coverage for treatments and therapeutics and the progress that UK science have made in studying Covid-19, particularly Synairgen with their inhaled version on Interferon Beta SNG001.
A Great UK story.
Yours Faithfully,
Sign In
Follow the stocks
